Search Results 2001-2010 of 19592 for Hemoglobin

1. MEDI5395 Advanced Solid Tumors - Clinical Trials

   Hemoglobin ≥ 9 g/dL;; Platelets ≥ 100,000/μL;; Hepatic ALT ≤ 2.5 × ULN;; AST ≤ 2.5 × ULN;; TBL ≤ 1.5 × ULN [≤ 3 × ULN if the subject has documented ...

2. Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma - Mayo Clinic

   Hemoglobin (Hb) ≥ 8 g/dL;; Platelets (PLT) ≥ 75 × 10^9 /L or ≥ 50 × 10^9 /L in case of documented bone marrow involvement (> 50% or tumor cells), without ...

3. A Study to Evaluate Safety and Effectiveness of SHP647 as Induction Therapy in Participants with Moderate-to- Severe Crohn's Disease - Mayo Clinic

   Total bilirubin level ≥ 1.5 x ULN or > 2.0 x ULN if the subject has a known documented diagnosis history of Gilbert's syndrome). Hemoglobin level ≤ 80 g/L ( ...

4. A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130) - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL;; Patients may be transfused to meet this criterion;; INR or aPTT ≤ 1.5 x upper limit of normal (ULN). This applies only to patients ...

5. A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

   Hemoglobin < 8 g/dL;; Platelets < 100,000/µL. Positive serum pregnancy test at the Screening visit or positive urine pregnancy test at the Baseline visit. No ...

6. Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma - Mayo Clinic

   Hemoglobin* ≥ 9 g/dL; Platelets** ≥ 100 000/mm^3 (≥ 100 × 10^9 /L); ANC*** ≥ 1000/mm^3 (≥ 1.0 × 10^9 /L). Hematologic function (Coagulation Factors). INR ...

7. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL;; NOTE: Must be met without growth factor support and no transfusions < 14 days prior to testing; Absolute neutrophil count (ANC) ...

8. A Global, Randomized, Placebo-controlled Phase 3 Study of Fruquintinib in Patients with Refractory Metastatic Colorectal Cancer - Mayo Clinic

   Hemoglobin < 9.0 g/dL. Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed. Serum ...

9. Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary - Mayo Clinic

   Hemoglobin (Hgb) ≥ 8.5 g/dL without transfusion or EPO dependency (≤ 7 days prior to assessment); Platelets ≥ 90,000 / mcL; Creatinine OR Calculated ...

10. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...